Literature DB >> 11551937

The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site.

C G Beck1, C Studer, J F Zuber, B J Demange, U Manning, R Urfer.   

Abstract

Monocyte chemoattractant protein-1 (MCP-1) is a chemotactic cytokine mainly acting on monocytes and T cells that elicits its biological effects by interacting with the seven-transmembrane helix receptor CCR2B. The vaccinia virus strain Lister and many other poxviruses express soluble proteins (vCCI) that bind MCP-1 and other CC chemokines and inhibit their function. In order to define the interaction site of MCP-1 with vCCI from vaccinia, surface exposed residues of MCP-1 were identified and mutated to alanine. The MCP-1 variants were expressed, purified, and their interaction with vCCI was characterized. The site on MCP-1 for vCCI binding is dominated by arginine 18 with important additional contributions from tyrosine 13 and arginine 24. These residues define a binding site that largely overlaps with the CCR2B receptor interaction site. The viral chemokine-binding protein vCCI thus inhibits the biological function of MCP-1 by directly masking its CCR2B receptor-binding site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11551937     DOI: 10.1074/jbc.M106305200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

Review 1.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

2.  Identification of the pharmacophore of the CC chemokine-binding proteins Evasin-1 and -4 using phage display.

Authors:  Pauline Bonvin; Steven M Dunn; François Rousseau; Douglas P Dyer; Jeffrey Shaw; Christine A Power; Tracy M Handel; Amanda E I Proudfoot
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

3.  Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta.

Authors:  Li Zhang; Michele Derider; Melissa A McCornack; Shu-Chuan Jao; Nancy Isern; Traci Ness; Richard Moyer; Patricia J LiWang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

4.  Structural insights into the interaction between a potent anti-inflammatory protein, viral CC chemokine inhibitor (vCCI), and the human CC chemokine, Eotaxin-1.

Authors:  Nai-Wei Kuo; Yong-Guang Gao; Megan S Schill; Nancy Isern; Cynthia M Dupureur; Patricia J Liwang
Journal:  J Biol Chem       Date:  2014-01-30       Impact factor: 5.157

5.  Crystallization and preliminary X-ray analysis of the chemokine-binding protein from orf virus (Poxviridae).

Authors:  Rafael Miguez Couñago; Stephen B Fleming; Andrew A Mercer; Kurt L Krause
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-06-24

6.  Structural determinants of chemokine binding by an Ectromelia virus-encoded decoy receptor.

Authors:  Phoebe L Arnold; Daved H Fremont
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

7.  Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors.

Authors:  Bruce T Seet; Catherine A McCaughan; Tracy M Handel; Andrew Mercer; Craig Brunetti; Grant McFadden; Stephen B Fleming
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 8.  Subversion of cytokine networks by virally encoded decoy receptors.

Authors:  Megan L Epperson; Chung A Lee; Daved H Fremont
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

9.  Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade.

Authors:  Gemma E White; Eileen McNeill; Ivy Christou; Keith M Channon; David R Greaves
Journal:  Mol Pharmacol       Date:  2011-05-17       Impact factor: 4.436

10.  The gammaherpesvirus chemokine binding protein binds to the N terminus of CXCL8.

Authors:  Louise M C Webb; Ian Clark-Lewis; Antonio Alcami
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.